{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Table+Salt&page=3", "query": { "intervention": "Standard Table Salt", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 129, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Table+Salt&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Table+Salt&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T19:59:51.650Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04390399", "title": "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "N-803", "type": "BIOLOGICAL" }, { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Irinotecan liposome", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2020-07-21", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 4, "location_summary": "El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390399" }, { "nct_id": "NCT04438551", "title": "Software Application for Low-Sodium Diet Trial (SALT)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Stone", "Hypernatriuria" ], "interventions": [ { "name": "Standard dietary counseling", "type": "BEHAVIORAL" }, { "name": "Mobile app", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-02-12", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04438551" }, { "nct_id": "NCT07705919", "title": "DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gadolinium-Chelate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Point-of-care portable perfusion phantom (P4)", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-10-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705919" }, { "nct_id": "NCT04704336", "title": "Integration of Hypertension Management Into HIV Care in Nigeria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Immunodeficiency Virus", "Hypertension" ], "interventions": [ { "name": "Task-shifting strategy for HTN control (TASSH) protocol", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 830, "start_date": "2021-09-13", "completion_date": "2026-01-31", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704336" }, { "nct_id": "NCT02620865", "title": "BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Antibody Therapy", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2015-12", "completion_date": "2021-06-21", "has_results": true, "last_update_posted_date": "2023-05-15", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620865" }, { "nct_id": "NCT03690921", "title": "Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Canal Squamous Cell Carcinoma", "Stage I Anal Cancer AJCC v8", "Stage II Anal Cancer AJCC v8", "Stage IIA Anal Cancer AJCC v8", "Stage IIB Anal Cancer AJCC v8", "Stage III Anal Cancer AJCC v8", "Stage IIIA Anal Cancer AJCC v8", "Stage IIIB Anal Cancer AJCC v8", "Stage IIIC Anal Cancer AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 8, "start_date": "2018-11-08", "completion_date": "2022-06-03", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03690921" }, { "nct_id": "NCT02389959", "title": "Intranasal Bevacizumab for HHT-Related Epistaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HHT", "Hereditary Hemorrhagic Telangiectasia", "Epistaxis", "Nose Bleeds", "Nasal Bleeding" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Placebo (Saline)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2014-08-04", "completion_date": "2020-01-23", "has_results": true, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02389959" }, { "nct_id": "NCT07220382", "title": "Preoperative BOTOX® Injection for Large Ventral Hernia Repair", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hernia Abdominal Wall", "Botox Injection", "Hernia Incisional Ventral", "Hernia Repair With Compartment Syndrome", "Hernia Surgery", "Hernia", "Hernia Incisional" ], "interventions": [ { "name": "OnabotulinumtoxinA Injection", "type": "PROCEDURE" }, { "name": "Saline (placebo) Injection", "type": "PROCEDURE" }, { "name": "OnabotulinumtoxinA", "type": "DRUG" }, { "name": "0.9 % Normal Saline", "type": "DRUG" }, { "name": "Open Ventral Hernia Repair", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2025-11-03", "completion_date": "2029-12-15", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220382" }, { "nct_id": "NCT06423326", "title": "Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage I Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pancreatic Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-08-06", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06423326" }, { "nct_id": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Salvage Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-04-24", "completion_date": "2033-02-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-17T19:59:51.650Z", "location_count": 113, "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 83 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195734" } ] }